- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), PDAC, CRC, NSCLC, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Solid Tumors
- Interventions
- RMC-5127, daraxonrasib, cetuximab
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 574 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 404
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
- Interventions
- Biospecimen Collection, Cholestyramine, Computed Tomography, Diagnostic Imaging, Gemcitabine, Leflunomide, Magnetic Resonance Imaging
- Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Emavusertib, Gemcitabine Hydrochloride, Nab-paclitaxel
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 26
- States / cities
- Duarte, California • Irvine, California • Orange, California + 18 more
- Conditions
- Pancreatic Neoplasms
- Interventions
- Vitamin E δ-Tocotrienol
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Biliary Tract Diseases, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Barrett Esophagus
- Interventions
- ExSpiron Respiratory Variation Monitor
- Device
- Lead sponsor
- Donald Mathews
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma, Ovarian Serous Adenocarcinoma, Biliary Cancer Metastatic, Ovarian Serous Cystadenocarcinoma
- Interventions
- ZB131
- Drug
- Lead sponsor
- ZielBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 6 more
- Conditions
- Adenocarcinoma, Carcinoma, Pancreatic Ductal
- Interventions
- Relacorilant, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Orange, California + 16 more
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- [18F]FAPI-74 PET/CT
- Drug
- Lead sponsor
- SOFIE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 16
- States / cities
- Cerritos, California • Duarte, California • Irvine, California + 12 more
- Conditions
- Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
- Interventions
- Pembrolizumab, Defactinib
- Drug
- Lead sponsor
- Lei Zheng
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Baltimore, Maryland • San Antonio, Texas
- Conditions
- Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- Zentalis, Gemzar
- Drug
- Lead sponsor
- Brandon Huffman, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pancreatic Ductal Adenocarcinoma, Oligometastatic Disease
- Interventions
- Surgery
- Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- Paclitaxel, NALIRIFOX
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Autologous Mesothelin-specific TCR-T Cells, Cyclophosphamide, Fludarabine, Bendamustine
- Biological · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Pancreatic Cancer
- Interventions
- Oxaliplatin, Irinotecan, Folinic Acid, 5-Fluorouracil (5-FU), NC410, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- RO7496353, Atezolizumab, Capecitabine, S-1, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Pegcetacoplan
- Procedure · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Colorectal Cancer, Gastric Cancers, Ovarian Cancers, Pancreatic Ductal Adenocarcinoma
- Interventions
- GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Pegvorhyaluronidase alfa, Abraxane, Gemcitabine
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pancreatic Adenocarcinoma Metastatic
- Interventions
- Niraparib, FOLFIRI, Ipilimumab
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania
- Conditions
- Familial Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm
- Interventions
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol
- Procedure · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Pancreatic Ductal Adenocarcinoma, Sarcoma
- Interventions
- Decitabine, Gemcitabine
- Drug
- Lead sponsor
- Mohammed Milhem
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Stage III Pancreatic Cancer
- Interventions
- SOC, NanoKnife System
- Drug · Device
- Lead sponsor
- Angiodynamics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 14
- States / cities
- La Jolla, California • Gainesville, Florida • Miami, Florida + 10 more
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Onvansertib, Nanoliposomal irinotecan, Leucovorin, Fluorouracil
- Drug
- Lead sponsor
- Cardiff Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Westwood, Kansas + 3 more
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)
- Interventions
- Adaptive Radiation Therapy
- Radiation
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania